REVIEW article
Front. Microbiol.
Sec. Phage Biology
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1632560
This article is part of the Research TopicHarnessing Bacteriophages and Phage-Engineered Products for Antibacterial and Anticancer Therapies: Challenges and OpportunitiesView all 7 articles
Advancements in research leveraging phage display technology for gastric cancer diagnosis and treatment
Provisionally accepted
- Shenzhen Institute for Drug Control Shenzhen Testing Center of Medical Devices, Shenzhen Institute For Drug Control, Shenzhen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Gastric cancer persists as a major global health challenge, ranking among the leading causes of cancer-related deaths worldwide. The high mortality rate primarily stems from difficulties in early detection, often resulting in late-stage diagnosis when treatment options are limited. Phage display technology, developed in 1985, has emerged as a powerful tool in gastric cancer research, facilitating significant advances in three key areas: (1) identification of novel biomarkers for early detection, (2) screening of targeted therapeutic molecules, and (3) development of diagnostic reagents. This comprehensive review examines current applications of phage display in both diagnostic and therapeutic approaches for gastric cancer, while critically analyzing existing limitations in sensitivity, specificity, library diversity, and screening efficiency. Furthermore, we discuss the promising potential of integrating phage display with other cutting-edge technologies, proposing future research directions that could enhance its clinical utility and ultimately improve patient outcomes in gastric cancer management.
Keywords: phage display, gastric cancer, diagnosis, Treatment, biomarker, targeting
Received: 22 May 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 Wang, Li, Lin, Deng, Liu and Ji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuan Ji, Shenzhen Institute for Drug Control Shenzhen Testing Center of Medical Devices, Shenzhen Institute For Drug Control, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.